MSB_logo_notag (001).jpg
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
January 11, 2022 20:26 ET | Mesoblast Limited
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced 36-month follow-up...
MSB_logo_notag (001).jpg
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
December 30, 2021 18:38 ET | Mesoblast Limited
Key Points: Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC)...
MSB_logo_notag (001).jpg
FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program
December 15, 2021 19:09 ET | Mesoblast Limited
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received...
MSB_logo_notag (001).jpg
Update on Novartis Agreement
December 13, 2021 19:18 ET | Mesoblast Limited
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it...
MSB_logo_notag (001).jpg
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
December 05, 2021 18:47 ET | Mesoblast Limited
Key points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest...
MSB_logo_notag (001).jpg
Operational Highlights and Financial Results for the Period Ended September 30, 2021
November 23, 2021 18:09 ET | Mesoblast Limited
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
MSB_logo_notag (001).jpg
Mesoblast Corporate Update and Financial Results Webcast
November 23, 2021 07:18 ET | Mesoblast Limited
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
MSB_logo_notag (001).jpg
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
November 21, 2021 19:31 ET | Mesoblast Limited
NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has...
mesoblast logo.jpg
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
November 14, 2021 19:13 ET | Mesoblast Limited
Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation NEW YORK, Nov. 14, 2021 (GLOBE NEWSWIRE) --...
mesoblast logo.jpg
Appendix 4C Quarterly Activity Report
October 28, 2021 19:51 ET | Mesoblast Limited
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...